{
  "id": 17869867,
  "title": "Eli Lilly Stock: Is It Still a Buy at $1,400?",
  "url": "https://urgent.news/2026/11/02/eli-lilly-stock-is-it-still-a-buy-at-1-400",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-02T23:00:02.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/investing/2026/11/02/eli-lilly-stock-is-it-still-a-buy-at-1-400/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": "Eli Lilly stock recently reached an all-time high of over $1,400, signaling strong growth potential for the healthcare company. The latest quarterly numbers revealed impressive year-over-year growth, with revenue reaching $24.4 billion, a 39% increase from the previous period. However, the company's high valuation may have already priced in significant growth, making it riskier for investors. The revenue from Eli Lilly's GLP-1 products, Mounjaro and Zepbound, accounted for roughly two-thirds of the company's total sales, amounting to $16.1 billion. Management has revised its full-year guidance to $91 to $92 billion, but lowered earnings-per-share guidance by $0.50 to between $35 and $36. Given the stock's 45 times trailing earnings ratio, a considerable portion of future growth may already be priced in, limiting potential upside and increasing risk. While Eli Lilly remains a potential long-term investment, investors should approach the stock cautiously and manage their expectations for near-term performance.",
  "summary": "The company just released some incredible quarterly results, but its valuation is also fairly high.",
  "key_points": [
    "Eli Lilly stock hit $1,400 all-time high",
    "39% revenue growth year-over-year to $24.4B",
    "GLP-1 products Mounjaro and Zepbound drove $16.1B sales"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Nasdaq Markets",
        "title": "Eli Lilly Stock: Is It Still a Buy at $1,400?",
        "url": "https://urgent.news/2026/11/02/eli-lilly-stock-is-it-still-a-buy-at-1-400-17878438",
        "published": "2026-11-02T23:20:02.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}